Finance News World

Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) Market

Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) is a rare and progressive form of glomerular disease marked by immune complex deposition and complement activation, leading to chronic kidney damage. Often presenting with proteinuria, hematuria, and declining renal function, IC-MPGN poses diagnostic and therapeutic challenges due to its heterogeneous nature and overlapping features with other kidney disorders.

DelveInsight’s “IC-MPGN – Market Insights, Epidemiology, and Market Forecast – 2034” delivers a deep dive analysis of the evolving disease landscape, highlighting epidemiological patterns across major geographies such as the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. The report explores current diagnostic criteria, clinical management practices, and the ongoing shift towards precision nephrology.

Despite the limited availability of disease-specific therapies, ongoing research into the role of complement pathways and immune modulation is opening new therapeutic avenues. The IC-MPGN market is expected to witness steady progress fueled by improved diagnostic tools, patient registry expansion, and a growing pipeline of targeted treatments. This report offers essential insights for nephrologists, researchers, biopharma stakeholders, and decision-makers aiming to navigate this complex and underserved renal condition.

Some of the Key Facts of the Immune Complex Membranoproliferative Glomerulonephritis Market Report:

• The IC-MPGN market in the 7MM is expected to grow at a notable CAGR from 2023 to 2034.

• In 2023, the U.S. market size for IC-MPGN was approximately USD 12 million, projected to rise by 2034 due to increasing diagnosed prevalence and the launch of high-cost emerging therapies.

• The total diagnosed prevalent population of IC-MPGN in the 7MM was around 7,100 cases in 2023, with the United States accounting for roughly 55% (~3,770 cases), followed by Japan.

• Among the EU4 and the UK, Germany had the highest number of diagnosed cases in 2023, followed by Spain, while Italy had the fewest.

• In 2023, males accounted for approximately 52% of all diagnosed IC-MPGN cases in the United States.

• In April 2025, the FDA granted Priority Review to pegcetacoplan (Empaveli), a C3/C3b inhibitor, for the treatment of C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN). This designation is given to therapies for serious conditions that, if approved, offer significant improvements in treatment or outcomes.

• In March 2025, the FDA approved Fabhalta (iptacopan) by Novartis as the first authorized treatment for C3 glomerulopathy (C3G) in adults, offering a new option to reduce proteinuria in this rare kidney disease.

• Leading companies in the immune complex membranoproliferative glomerulonephritis market include Novartis Pharmaceuticals, Apellis Pharmaceuticals, and others.

• Emerging acute immune complex membranoproliferative glomerulonephritis drugs include Iptacopan (LNP023), Pegcetacoplan (APL-2), and others.

• The rising incidence of immune complex membranoproliferative glomerulonephritis (iC-MPGN), coupled with ongoing advancements in diagnostic precision and therapeutic innovation, is fueling the need for more targeted and effective treatment strategies.

To know in detail about the immune complex membranoproliferative glomerulonephritis market outlook, drug uptake, treatment scenario, and epidemiology trends, click here: Immune Complex Membranoproliferative Glomerulonephritis Market Forecast

Immune Complex Membranoproliferative Glomerulonephritis Overview

Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) is a rare, progressive kidney disorder characterized by the deposition of immune complexes in the glomeruli, leading to chronic inflammation and injury. It primarily affects children and young adults, though it can occur at any age. IC-MPGN is marked histologically by mesangial cell proliferation and thickening of the glomerular basement membrane. Patients often present with symptoms such as proteinuria, hematuria, hypertension, and declining renal function. If left unmanaged, IC-MPGN can progress to end-stage renal disease (ESRD), requiring dialysis or transplantation.

The pathogenesis of IC-MPGN is complex and often associated with chronic infections, autoimmune diseases, or monoclonal gammopathy. Diagnosis typically relies on kidney biopsy, immunofluorescence, and complement studies to distinguish it from other forms of MPGN. Despite advancements in nephrology, treatment remains challenging due to limited targeted therapies. Current management involves immunosuppressive agents, RAAS inhibitors, and supportive care. However, with a growing understanding of complement dysregulation and immune mechanisms, new therapies are being explored, making the IC-MPGN landscape an area of active clinical and research interest.

Get a free sample of the Immune complex membranoproliferative glomerulonephritis market report with key insights and emerging therapies here: https://www.delveinsight.com/report-store/immune-complex-membranoproliferative-glomerulonephritis-ic-mpgn-market

Immune Complex Membranoproliferative Glomerulonephritis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Immune Complex Membranoproliferative Glomerulonephritis Epidemiology Segmentation:

The Immune Complex Membranoproliferative Glomerulonephritis epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by:

• Total Incident Cases of IC-MPGN

• Total Gender-specific Cases of IC-MPGN

• Total Region-specific Cases of IC-MPGN

• Total Treated Cases of IC-MPGN

Download the report to understand which factors are driving immune complex membranoproliferative glomerulonephritis epidemiology trends @ Immune Complex Membranoproliferative Glomerulonephritis Epidemiology Forecast

Immune Complex Membranoproliferative Glomerulonephritis Drugs Uptake and Pipeline Development Activities

The immune complex membranoproliferative glomerulonephritis drugs uptake section examines the rate at which newly launched or upcoming potential drugs are being adopted in the immune complex membranoproliferative glomerulonephritis market during the study period. This analysis covers drug uptake, patient adoption of therapies, and the sales performance of each drug.

Additionally, the therapeutics assessment section highlights the drugs with the most rapid uptake, shedding light on the factors driving their widespread use. It also provides a comparative analysis of these drugs based on their market share.

The report further delves into the immune complex membranoproliferative glomerulonephritis pipeline development activities, offering key insights into various therapeutic candidates in different stages of development and the major companies behind these innovations. It also covers recent collaborations, acquisitions, mergers, licensing agreements, patent details, and other critical information related to emerging therapies.

Immune Complex Membranoproliferative Glomerulonephritis Market Outlook

The treatment landscape for Immune Complex-Mediated Membranoproliferative Glomerulonephritis (IC-MPGN) remains largely underserved, with no approved therapies currently available. Most patients rely on off-label immunosuppressants, RAAS inhibitors, and supportive treatments, which offer only limited benefit in slowing disease progression. Given the disease’s association with complement pathway dysregulation, targeted complement inhibition presents a promising therapeutic avenue.

The market is gradually evolving, fueled by growing awareness of the disease’s pathophysiology and a push for more precise treatments. Notably, two potential therapies—Iptacopan (Novartis Pharmaceuticals) and Pegcetacoplan (Apellis Pharmaceuticals)—have reached Phase III trials, signaling progress toward more effective, disease-modifying interventions. As research advances and clinical trials mature, the IC-MPGN market is poised for transformation, offering hope to patients facing a high risk of kidney failure and limited treatment options.

Immune Complex Membranoproliferative Glomerulonephritis Market Strengths

• The development of novel complement inhibitors such as Iptacopan and Pegcetacoplan in Phase III trials marks a promising shift toward disease-specific treatment, addressing the core pathophysiology of IC-MPGN.

• Growing awareness among nephrologists and researchers about complement dysregulation in IC-MPGN is driving both diagnostic improvements and investment in specialized therapeutic approaches.

Immune Complex Membranoproliferative Glomerulonephritis Market Weaknesses

• The absence of any FDA or EMA-approved treatments for IC-MPGN leaves patients reliant on off-label and largely ineffective immunosuppressive regimens, contributing to poor long-term outcomes.

• As an ultra-rare disease, IC-MPGN faces challenges related to low prevalence, limited clinical trial enrollment, and sparse real-world evidence, which can hinder drug development and commercialization efforts.

Scope of the Immune Complex Membranoproliferative Glomerulonephritis Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Immune Complex Membranoproliferative Glomerulonephritis Companies: Novartis Pharmaceuticals, Apellis Pharmaceuticals, and others.

• Key Immune Complex Membranoproliferative Glomerulonephritis Therapies: Iptacopan (LNP023), Pegcetacoplan (APL-2), and others.

• Immune Complex Membranoproliferative Glomerulonephritis Therapeutic Assessment: Immune Complex Membranoproliferative Glomerulonephritis, currently marketed, and Immune Complex Membranoproliferative Glomerulonephritis emerging therapies

• Immune Complex Membranoproliferative Glomerulonephritis Market Dynamics: Immune Complex Membranoproliferative Glomerulonephritis market drivers and Immune Complex Membranoproliferative Glomerulonephritis market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Immune Complex Membranoproliferative Glomerulonephritis Unmet Needs, KOL’s views, Analyst’s views, Immune Complex Membranoproliferative Glomerulonephritis Market Access and Reimbursement

To learn more about the key players and advancements in the Immune Complex Membranoproliferative Glomerulonephritis treatment landscape, visit the Immune Complex Membranoproliferative Glomerulonephritis Market Analysis Report

Table of Contents

1. Immune Complex Membranoproliferative Glomerulonephritis Market Report Introduction

2. Executive Summary for Immune Complex Membranoproliferative Glomerulonephritis

3. SWOT analysis of Immune Complex Membranoproliferative Glomerulonephritis

4. Immune Complex Membranoproliferative Glomerulonephritis Patient Share (%) Overview at a Glance

5. Immune Complex Membranoproliferative Glomerulonephritis Market Overview at a Glance

6. Immune Complex Membranoproliferative Glomerulonephritis Disease Background and Overview

7. Immune Complex Membranoproliferative Glomerulonephritis Epidemiology and Patient Population

8. Country-Specific Patient Population of Immune Complex Membranoproliferative Glomerulonephritis

9. Immune Complex Membranoproliferative Glomerulonephritis Current Treatment and Medical Practices

10. Immune Complex Membranoproliferative Glomerulonephritis Unmet Needs

11. Immune Complex Membranoproliferative Glomerulonephritis Emerging Therapies

12. Immune Complex Membranoproliferative Glomerulonephritis Market Outlook

13. Country-Wise Immune Complex Membranoproliferative Glomerulonephritis Market Analysis (2020–2034)

14. Immune Complex Membranoproliferative Glomerulonephritis Market Access and Reimbursement of Therapies

15. Immune Complex Membranoproliferative Glomerulonephritis Market Drivers

16. Immune Complex Membranoproliferative Glomerulonephritis Market Barriers

17. Immune Complex Membranoproliferative Glomerulonephritis Appendix

18. Immune Complex Membranoproliferative Glomerulonephritis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefit from market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Jatin Vimal
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/